The Histone Deacetylase Inhibitor Valproic Acid Lessens NK Cell Action against Oncolytic Virus-Infected Glioblastoma Cells by Inhibition of STAT5/T-BET Signaling and Generation of Gamma Interferon

Prolonged Microglial Cell Activation and Lymphocyte Infiltration following Experimental Herpes Encephalitis

(2014) C. P. Marques et al.   JOURNAL OF IMMUNOLOGY

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

(2011) D. Ostertag et al.   NEURO-ONCOLOGY

Oncolytic viruses and histone deacetylase inhibitors—A multi-pronged strategy to target tumor cells

(2010) Thi Lien-Anh Nguyen et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Bone Marrow Mesenchymal Stem Cells Loaded With an Oncolytic Adenovirus Suppress the Anti-adenoviral Immune Response in the Cotton Rat Model

(2010) Atique U Ahmed et al.   MOLECULAR THERAPY

Targeting Localized Immune Suppression Within the Tumor Through Repeat Cycles of Immune Cell-oncolytic Virus Combination Therapy

(2010) Stephen H Thorne et al.   MOLECULAR THERAPY

Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis

(2009) Cai Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pharmacologic and Chemical Adjuvants in Tumor Virotherapy

(2009) Christopher Alvarez-Breckenridge et al.   CHEMICAL REVIEWS

Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide

(2009) X. Q. Lun et al.   CLINICAL CANCER RESEARCH

Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cellsin vitro

(2009) Brigitte Kircher et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Converting Tumor-specific Markers Into Reporters of Oncolytic Virus Infection

(2009) Ianko D Iankov et al.   MOLECULAR THERAPY

The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development

(2008) I.-K. Park et al.   BLOOD

Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

(2008) J. Qiao et al.   CLINICAL CANCER RESEARCH

Oncolytic HSV-1 Infection of Tumors Induces Angiogenesis and Upregulates CYR61

(2008) Kazuhiko Kurozumi et al.   MOLECULAR THERAPY

Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses

(2008) Akihiro Otsuki et al.   MOLECULAR THERAPY

Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects

(2008) Ta-Chiang Liu et al.   MOLECULAR THERAPY

A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas

(2008) Peter Forsyth et al.   MOLECULAR THERAPY

Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM

(2008) James M Markert et al.   MOLECULAR THERAPY

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16

(2008) M Aghi et al.   ONCOGENE

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis

(2008) T. L.-A. Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exponential Enhancement of Oncolytic Vesicular Stomatitis Virus Potency by Vector-mediated Suppression of Inflammatory Responses In Vivo

(2007) Jennifer Altomonte et al.   MOLECULAR THERAPY